Are RPI’s days numbered – what could this mean for pension schemes?

In its recent White Paper, the Government firmly shut the door on a statutory override allowing schemes to switch from RPI to CPI. In this note we look at what the future might hold for RPI, in particular how likely is it that RPI might change or be discontinued.

Background

At present, three main consumer price indices are produced monthly by the Office for National Statistics (ONS). The Retail Prices Index (RPI) was the main UK inflation measure for many years and dates back to the 1940s. The Consumer Prices Index (CPI) is required by EU regulations, was first published in the UK in 1997 and has been the basis of the Bank of England’s (BOE) inflation target since 2003. CPIH is a variant of CPI that was introduced in 2013 which includes an allowance for owner occupiers’ housing costs (OOH).

RPI has been on the receiving end of some criticism in recent years, much of it centred on shortcomings in the Carli averaging formula, which it uses (unlike CPI). Back in 2012, the UK Statistics Authority (UKSA) concluded that RPI does not meet statistical best practice. Following that, in 2015 , Paul Johnson, in his independent review of consumer price indices, agreed with this view, recommending that the ONS should move towards making CPIH its headline rate of inflation and that ‘Government and regulators should work towards ending the use of RPI as soon as practicable’. Finally, in 2016, the National Statistician stated that he believed ‘RPI is not a good measure of inflation and does not realistically have the potential to become one’. In the interests
of balance, it should be noted that CPI is also not without its critics, one shortcoming being that it does not include OOH costs (hence the introduction of CPIH).

Recent developments

Comments from Mark Carney

In January, Mark Carney, the Governor of the Bank of England, whilst giving evidence to a Parliamentary committee, was asked whether he was surprised that the ONS seemed to be ‘unwilling to correct known errors’ in RPI. Carney said that ‘[a]t the moment, we have RPI, which most would acknowledge has known errors. We have CPI, which is what virtually everyone recognises and is in our remit. Then there is the ONS’s favourite, if you will, the CPIH, which includes housing costs. At some point, it would be good to consolidate the focus on to one. Lest anyone thinks I am advocating changing the inflation target to CPIH, I am not at this stage, because it does not have the track record in place.’

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Xafinity Plc

    More articles like this

    Fidelity Japan Trust

    Japanese stocks set to rise after reaching record highs

    After topping bubble-era highs, Goldman Sachs Research says Japanese stocks are poised to rise even higher. Japan’s Nikkei 225 stock index closed above 40,000 on March 4, setting another record high after climbing last month above

    Norcros Plc

    Norcros plc enhances Market Presence with Strategic Moves

    Norcros plc (LON:NXR), a prominent supplier of innovative bathroom and kitchen products, continues to make strategic moves to enhance its market presence and financial performance. The recent disposal of Johnson Tiles UK to its management team marks

    Accrol Group

    What are the latest technology trends in manufacturing?

    We asked the FactoryTech 50 and judging panel to describe a particular trend they have noticed in manufacturing technology in the last year. Judge Kevin Smith (below) is lead technology advisor at Made Smarter UK, which has engaged

    Team plc

    Key Insurance Types in Financial Planning

    When it comes to financial planning, different types of insurance serve different purposes. While critical illness insurance can be valuable, the importance of each insurance type may vary depending on a clients individual circumstances and priorities.

    Poolbeg Pharma granted significant POLB 001 patent in United States

    Poolbeg Pharma plc (LON:POLB, OTCQB:POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that, further to its announcement on 20 March 2024, the Company has received the fully granted